Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months

This publication has 10 references indexed in Scilit:

• When to randomize?
  Journal of Clinical Oncology, 1991
• Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer
  The Lancet, 1990
• Microcomputer-assisted univariate survival data analysis using Kaplan-Meier life table estimators
  Computer Methods and Programs in Biomedicine, 1988
• Distant Recurrence in Breast Cancer: Survival expectations and first choice of chemotherapy regimen
  Acta Oncologica, 1988
• Improving the Quality of Life during Chemotherapy for Advanced Breast Cancer
  New England Journal of Medicine, 1987
• Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized study of CMF vs CMF plus tamoxifen
  European Journal of Cancer and Clinical Oncology, 1985
• A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer A Cancer and Leukemia Group B study
  American Journal of Clinical Oncology, 1984
• IMPACT OF CHEMOTHERAPY ON SURVIVAL IN METASTATIC BREAST CANCER
  The Lancet, 1980
• Cancer of the Breast
  New England Journal of Medicine, 1980
• Assessment of response to therapy in advanced breast cancer.A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland
  Cancer, 1977